 |
|
|
| |
IL28B SNP Geographical Distribution and Antiviral Responses in a 28-day Phase 2a Trial of PSI-7977 Daily Dosing plus PEG-IFN/RBV
|
| |
| |
Reported by Jules Levin
AASLD 2010 Nov 1 Boston
McHutchison JG1, Goldstein DB2, Shianna K2, Lawitz E3, Lalezari J4, Rodriguez-Torres M5, Kowdley KV6, Nelson DR7, DeJesus E8, Mader M9, Albanis E9, Symonds WT9, Berrey MM9
1. Duke Clinical Research Institute, Durham, NC 2. The Institute for Genome Science and Policy at Duke University 3. Alamo Medical Research, San Antonio, TX 4. Quest Clinical Research, San Francisco, CA 5. Fundacion de Investigacion de Diego, Santurce, PR, 6. Virginia Mason Medical Center, Seattle, WA 7. University of Florida, Gainesville, FL 8. Orlando Immunology Center, Orlando, FL 9. Pharmasset, Inc., Princeton, NJ
|
| |
|
|
|
|
|
